Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder, X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced the appointment of William Aliski and Wendy L. Dixon, Ph.D. to the company’s Board of Directors. Mr. Aliski, a global biotech executive and orphan disease expert, and Dr. Dixon, an industry veteran who has launched more than 20 pharmaceutical products, will serve as independent directors for Edimer. With these additions, Edimer extends gratitude and appreciation for the counsel provided by Dan Lynch who will now step down from his position on the Board.
Help employers find you! Check out all the jobs and post your resume.
